Bisphenol AF as an activator of human estrogen receptor β1 (ERβ1) in breast cancer cell lines
-
- Okazaki Hiroyuki
- Department of Molecular Biology, Daiichi University of Pharmacy
-
- Hirao-Suzuki Masayo
- Laboratory of Xenobiotic Metabolism and Environmental Toxicology, Faculty of Pharmaceutical Sciences, Hiroshima International University (HIU)
-
- Takeda Shuso
- Laboratory of Xenobiotic Metabolism and Environmental Toxicology, Faculty of Pharmaceutical Sciences, Hiroshima International University (HIU)
-
- Takemoto Yukimi
- Department of Molecular Biology, Daiichi University of Pharmacy
-
- Mizunoe Ramu
- Department of Molecular Biology, Daiichi University of Pharmacy
-
- Haraguchi Koichi
- Analytical Chemistry, Daiichi University of Pharmacy
-
- Watanabe Kazuhito
- Center for Supporting Pharmaceutical Education, Daiichi University of Pharmacy
-
- Takiguchi Masufumi
- Laboratory of Xenobiotic Metabolism and Environmental Toxicology, Faculty of Pharmaceutical Sciences, Hiroshima International University (HIU)
-
- Aramaki Hironori
- Department of Molecular Biology, Daiichi University of Pharmacy
この論文をさがす
説明
<p>Bisphenol AF (BPAF) is now recognized as one of the replacements for bisphenol A (BPA). Although considerable experimental evidence suggests that BPA is an endocrine-disrupting chemical, the toxicological profile of BPAF has been investigated in less detail than that of BPA, even at the in vitro level. BPAF has been established as an activator of estrogen receptor α (ERα) in many cell lines; however, controversy surrounds its effects on the other isoform, ERβ (i.e., whether it functions as a stimulator). Five human ERβ isoforms have been cloned and characterized. Of these, we focused on the interactions between BPAF and the two isoforms, ERβ1 and ERβ2. We demonstrated that i) BPAF functioned as a stimulator of ERβ1 (and ERα), which is transiently expressed in the two types of human breast cancer cells (MDA-MB-231 and SK-BR-3 cells) (EC50 values for ERβ: 6.87 nM and 2.58 nM, respectively, and EC50 values for ERα: 24.7 nM and 181 nM, respectively), ii) the stimulation of ERβ1 by BPAF (1-25 nM) was abrogated by PHTPP (an ERβ selective antagonist), and iii) the expression of ERβ1 and ERβ2 was not modulated by BPAF at nanomolar concentrations up to 25 nM. These results indicate that BPAF activates not only human ERα, but also the ERβ1 isoform in breast cancer cells, and exhibits higher activation potency for ERβ1.</p>
収録刊行物
-
- The Journal of Toxicological Sciences
-
The Journal of Toxicological Sciences 43 (5), 321-327, 2018
一般社団法人 日本毒性学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679880627840
-
- NII論文ID
- 130006733269
-
- NII書誌ID
- AN00002808
-
- ISSN
- 18803989
- 03881350
-
- NDL書誌ID
- 029175778
-
- PubMed
- 29743443
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可